COVID-19 and Hypercoagulability: Potential Impact on Management with Oral Contraceptives, Estrogen Therapy and Pregnancy.

Spratt, Daniel I; Buchsbaum, Rachel J

Spratt, Daniel I; Buchsbaum, Rachel J.

Spratt DI; The Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Maine Medical Center, Portland Maine.
Buchsbaum RJ; Division of Hematology/Oncology, Tufts University School of Medicine, Boston Massachusetts.

Endocrinology ; 161(12)2020 12 01.

Article in English | MEDLINE | ID: covidwho-684655

Subject(s)

Contraceptives, Oral, Hormonal/adverse effects; Coronavirus Infections/complications; Estrogens/adverse effects; Pneumonia, Viral/complications; Thrombophilia/etiology; Betacoronavirus/physiology; COVID-19; Contraceptives, Oral, Hormonal/administration & dosage; Coronavirus Infections/virology; Estrogens/administration & dosage; Female; Hormone Replacement Therapy/adverse effects; Humans; Male; Pandemics; Platelet Activation/drug effects; Platelet Aggregation/drug effects; Pneumonia, Viral/virology; Pregnancy; Pregnancy Complications, Infectious/etiology; Pregnancy Complications, Infectious/physiopathology; SARS-CoV-2; Thrombophilia/physiopathology

Keywords

COVID-19; coronavirus; estrogen therapy; hypercoagulability; oral contraceptives; pregnancy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Contraceptives, Oral, Hormonal / Thrombophilia / Estrogens Type of study: Experimental Studies Topics: Long Covid Limits: Female / Humans / Male / Pregnancy Language: English Year: 2020 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google